204
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab

ORCID Icon, , , , , ORCID Icon, & ORCID Icon show all
Pages 1583-1587 | Received 12 Dec 2022, Accepted 24 May 2023, Published online: 12 Jun 2023
 

Acknowledgements

This study was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748.

Disclosure statement

AM receives research funding from Incyte Corporation and Amryt Pharma; consults for ADC Therapeutics, Alira Health, Protagonist Therapeutics, OnQuality, and Janssen; and receives royalties from UpToDate. MBG receives research funding from Amgen, Actinium Pharmaceuticals, and Sanofi and has served in an advisory/consulting role for Sanofi, Novartis, and Allogene. ACK has received advisory/consulting fees from: Astellas and Blueprint Medicines. RP, SG, SD, MP, and EC have no conflicts of interest to disclose.

Data availability statement

Data are available within the article or its supplementary materials.

Additional information

Funding

This study was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.